GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Preferred Stock

Anixa Biosciences (Anixa Biosciences) Preferred Stock : $0.00 Mil (As of Apr. 2024)


View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Anixa Biosciences's preferred stock for the quarter that ended in Apr. 2024 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Anixa Biosciences's Enterprise Value for the quarter that ended in Apr. 2024 was $70.87 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Anixa Biosciences's Book Value per Share for the quarter that ended in Apr. 2024 was $0.74.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Anixa Biosciences's Earnings per Share (Diluted) for the three months ended in Apr. 2024 was $-0.10.


Anixa Biosciences Preferred Stock Historical Data

The historical data trend for Anixa Biosciences's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences Preferred Stock Chart

Anixa Biosciences Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anixa Biosciences Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Anixa Biosciences Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Anixa Biosciences  (NAS:ANIX) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Anixa Biosciences's Enterprise Value for the quarter that ended in Apr. 2024 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Anixa Biosciences's Book Value per Share for the quarter that ended in Apr. 2024 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Anixa Biosciences's Earnings per Share (Diluted) (EPS) for the three months ended in Apr. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anixa Biosciences Preferred Stock Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Anixa Biosciences (Anixa Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Executives
Amit Kumar director, officer: Chief Executive Officer C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani officer: COO & CFO 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr director 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk director 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan director
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams director C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox director 929 NOWITA PLACE, VENICE CA 90291
Andrea Belz director 1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender officer: Chief Operating Officer 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman officer: President and CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop officer: Sr. Vice President-Engineering C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson director 20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams director C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747